Global Head of Cell Therapy External Manufacturing and Strategic Sourcing
Kenneth Locke is Global Head of Cell Therapy External Manufacturing and Strategic Sourcing at Celgene, where he is responsible for leading the global sourcing team supporting the manufacturing and commercialization of chimeric antigen receptor (CAR) T cell (CAR T) therapies.
Prior to Celgene, Mr. Locke was Global Head of Procurement for Technical R&D and Cell & Gene Therapies at Novartis. He led both the technical development sourcing organization as well as a team supporting R&D and cGMP manufacturing for cell and gene therapy programs, including for Kymriah (tisagenlecleucel).
He first joined Novartis in 2009, holding various positions in global category management at the Novartis Institutes for Biomedical Research and as Global Head of Scientific Services Procurement. Prior to joining Novartis, Mr. Locke was with Bristol-Myers Squibb, where he held positions of increasing responsibility in global R&D procurement and strategic sourcing.
Prior to his career in procurement and supply chain, Mr. Locke worked as a research scientist in both the biotechnology and biopharmaceutical industries, including at Bristol-Myers Squibb, DuPont Pharmaceuticals (which was acquired by Bristol-Myers Squibb in 2001), Rhône-Poulenc Rorer (which merged with Hoechst AG to form Aventis in 1999), and 3 Dimensional Pharmaceuticals.
He holds a master of science in molecular miology from Lehigh University. He is a Certified Professional in Supply Management (CPSM) and a Certified Purchasing Manager (C.P.M) by the Institute for Supply Management (ISM).